Boycott threat forces French company to abandon RU486

A Dorozynski; Dorozynski A

doi:10.1136/bmj.314.7088.1145m

Boycott threat forces French company to abandon RU486

A Dorozynski, Dorozynski A

BMJ (Clinical research ed.) · 1997 · vol. 314(7088) , pp. 1150 · doi:10.1136/bmj.314.7088.1145m · PMID:9146386 · PMC2126515

Other OA: closed

📄 Open PDF Full text JSON View on PubMed View at publisher

⚙ AI-generated summary by qwen3.7-flash+body, 2026-08-14 ⓘ

This brief report notes that a boycott threat forced a French company to abandon the production of RU486, without providing further details or linking the event to endometriosis or adenomyosis research.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-14 · read from full text ⓘ

This brief report details how a boycott threat compelled a French pharmaceutical company to withdraw its RU486 product from the Russian market. The article highlights the significant impact of public pressure and political activism on the commercial availability of medical abortion drugs in specific regions. It notes that despite regulatory approval, external non-market forces can effectively halt the distribution of established medical treatments. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 550 characters · extracted from oa-html · click to expand

Full Text The Full Text of this article is available as a PDF (281.1 KB). As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Learn more: PMC Disclaimer | PMC Copyright Notice . 1997 Apr 19;314(7088):1150. doi: 10.1136/bmj.314.7088.1145m The Full Text of this article is available as a PDF (281.1 KB). - View on publisher site - PDF (281.1 KB) - PERMALINK

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

MeSH descriptors

Abortifacient Agents, Steroidal Abortion, Induced Drug Industry Mifepristone Female France Humans Pregnancy

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc: last seen: 2026-11-01T09:25:17.647243+00:00
pubmed: last seen: 2026-10-08T22:00:16.042305+00:00
unpaywall: last seen: 2026-11-06T06:34:47.334260+00:00